Loading...
XNYSAORT
Market cap1.25bUSD
Jan 10, Last price  
29.88USD
1D
-1.16%
1Q
15.28%
Jan 2017
56.03%
Name

Artivion Inc

Chart & Performance

D1W1MN
XNYS:AORT chart
P/E
P/S
3.54
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
2.27%
Rev. gr., 5y
6.14%
Revenues
354m
+12.82%
62,384,00069,282,00081,311,00094,763,000105,059,000111,685,000116,645,000119,626,000131,718,000140,763,000144,641,000145,898,000180,380,000189,702,000262,841,000276,222,000253,227,000298,836,000313,789,000354,004,000
Net income
-31m
L+59.91%
-18,749,000-19,535,000365,0007,201,00032,908,0008,679,0003,944,0007,371,0007,946,00016,172,0007,322,0004,005,00010,778,0003,704,000-3,805,0001,720,000-16,682,000-14,834,000-19,192,000-30,690,000
CFO
19m
P
-16,226,000-18,517,000-1,071,0009,292,0009,537,00016,572,00020,837,00016,751,00018,990,00016,772,0008,118,00011,442,00019,719,00010,803,0009,881,00015,827,00012,369,000-2,585,000-5,153,00018,825,000
Dividend
Dec 09, 20150.03 USD/sh
Earnings
Feb 13, 2025

Profile

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; and cardiac laser therapy products, such as SolarGen 2100s Console and SoloGrip III disposable handpieces. Further, the company sells CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as offers pyrolytic carbon coating services to other medical device manufacturers. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. Artivion Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.
IPO date
Feb 12, 1993
Employees
1,300
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
354,004
12.82%
313,789
5.00%
Cost of revenue
338,938
307,588
Unusual Expense (Income)
NOPBT
15,066
6,201
NOPBT Margin
4.26%
1.98%
Operating Taxes
9,104
4,208
Tax Rate
60.43%
67.86%
NOPAT
5,962
1,993
Net income
(30,690)
59.91%
(19,192)
29.38%
Dividends
Dividend yield
Proceeds from repurchase of equity
(559)
1,573
BB yield
0.08%
-0.32%
Debt
Debt current
5,428
5,429
Long-term debt
404,272
400,122
Deferred revenue
Other long-term liabilities
77,991
52,895
Net debt
350,760
366,200
Cash flow
Cash from operating activities
18,825
(5,153)
CAPEX
(7,430)
(10,715)
Cash from investing activities
(502)
(10,715)
Cash from financing activities
865
(1,639)
FCF
(51,453)
40,370
Balance
Cash
58,940
39,351
Long term investments
Excess cash
41,240
23,662
Stockholders' equity
(59,491)
(38,408)
Invested Capital
777,603
729,826
ROIC
0.79%
0.27%
ROCE
2.04%
0.87%
EV
Common stock shares outstanding
40,743
40,032
Price
17.88
47.52%
12.12
-40.44%
Market cap
728,485
50.14%
485,188
-38.84%
EV
1,079,245
851,388
EBITDA
38,142
28,643
EV/EBITDA
28.30
29.72
Interest
25,299
18,224
Interest/NOPBT
167.92%
293.89%